Short steroid course after first wheeze may stop asthma before it starts
NCT ID NCT03889743
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This trial tests whether giving the steroid dexamethasone for three days to children after their first severe wheezing episode (triggered by a rhinovirus) can prevent recurrent wheezing and asthma. The study enrolls children admitted to hospitals in Norway, Finland, and Sweden. Researchers will track how many children develop asthma or need regular asthma medication over the next two years.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a steroid drug called dexamethasone given as oral tablets for 3 days
- What this could lead to
- If it works, this could point toward a way to prevent asthma in children who have their first severe wheezing episode triggered by a common cold virus.
- What could go wrong
- This is a relatively small, early-stage trial, and the steroid may not reduce asthma risk or could have side effects. Results may not apply to all children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 280 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2019
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
3 to 23 months
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * admitted to pediatric acute wards in the participating hospitals in Norway, Finland, Sweden. * referred for first severe wheezing episode, defined as first-time acute breathing difficulty with wheezing ever, appearing less than 7 days from onset of symptoms * one or more of the following:(a) fever, (b) hypoxia (SAT O2 \<= 92%), (c) retractions (inter-, subcostal), (d) prolonged expiration (on auscultation), (e) expiratory rhonchi (on auscultation) * evidence of rhinovirus infection by PCR-test in nasopharyngeal secretions * signed informed consent and expected cooperation of the patients for the treatment and follow-up must be obtained and documented according to ICH GCP, and national/local regulations. Exclusion Criteria: * previous episodes with wheezing, defined as a history of acute breathing difficulty with wheezing in need of treatment at a general practitioner or at hospital, or parental information about similar breathing difficulties * gestational age \<37 weeks * chronic illness other than atopy (eczema), * previous systemic or inhaled corticosteroid treatment, * participation to another trial, * varicella infection or contact during the last 2-3 weeks, * need for intensive care unit treatment during the present infection, except for respiratory support with non-invasive methods (high flow nasal cannula ventilation, CPAP or BiPAP), * any reason why, in the opinion of the investigator, the patient should not participate (e.g. not able to comply with study procedures). * COVID-19 related disease.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Asthma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
8 sites in 3 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Akershus University Hospital
RECRUITINGOslo, Norway
-
Haukeland University Hospital
RECRUITINGBergen, Norway
-
Karolinska Universitetssjukhuset
RECRUITINGStockholm, Sweden
-
St Olavs Hospital
RECRUITINGTrondheim, Norway
-
Stavanger University Hospital
RECRUITINGStavanger, Norway
-
Turku University Hospital
RECRUITINGTurku, Finland
-
Ullevål University Hospital
RECRUITINGOslo, Norway
-
University Hospital of North Norway
RECRUITINGTromsø, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single triple inhaler tame asthma in the real world?
- Can a Three-Drug inhaler outperform the standard Two-Drug treatment for asthma?
- A handful of peanuts a day: could it sharpen teen brains?
- Can a new inhaler match Symbicort's performance?
- Herbal extract may turn gym sessions into stress relief and brain boost
- Fine-Mist inhalers aim to reach deep lungs in COPD